Incentivizing Novel Antibiotic Development–Netflix-Style

November 3, 2020

Drug makers have been increasingly disincentivized from developing novel antibiotics due to higher development costs and antibiotic stewardship programs, resulting in unmet need for new antibiotics. To meet this need, the National Institute for Health and Care Excellence (NICE), National Health Service (NHS) Improvement, and NHS England have launched a trial of a  pharmaceutical payment system for a Netflix-like antibiotic subscription model. This first-of-its-kind program aims to incentivize pharmaceutical manufacturers to develop novel antibiotic classes and products by providing a consistent revenue stream regardless of utilization. Read more here.

(Source: Xcenda Insights; 11/3/20)

Share This Story!